Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Kasper

Showing results (91-100 of 497) with videos related to

Pageof 50
Sort By:
International Clinical Psychopharmacology|July 21, 1998
Side effects, dropouts from treatment and cost consequencesS A Montgomery, S Kasper
Lancet (London, England)|December 3, 1994
Risperidone for Tourette's syndromeM Stamenkovic, H Aschauer, S Kasper
Science (New York, N.Y.)|August 5, 1977
Hexagonal (wurtzite) siliconJ S Kasper, R H Wentorf
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|October 6, 2001
Quetiapine: efficacy and tolerability in schizophreniaS Kasper, J Tauscher, A Heiden
Medical Hypotheses|February 14, 2004
Biophotons, microtubules and CNS, is our brain a "holographic computer"?F Grass, H Klima, S Kasper
Wiener Klinische Wochenschrift|March 28, 1997
[Maintenance therapy with 20 mg fluoxetine. Results of an administration study of 1,737 depressed patients]S Kasper, B Hesselmann, W Wein
International Journal of Psychiatry in Clinical Practice|June 14, 2014
Recurrent brief depression: A frequent syndrome in clinical practiceJ Angst, S Kasper, E Weiller
International Journal of Psychiatry in Clinical Practice|June 17, 2014
Physical signs in psychiatry: a step towards evidence-based medicineRk Gupta, R Kumar, S Kasper
Zentralblatt Fur Chirurgie|January 1, 1996
[History of autologous blood transfusion in the 19th century]S M Kasper, A S Kasper
International Clinical Psychopharmacology|July 19, 2001
Risperidone olanzapine drug outcomes studies in schizophrenia (RODOS): health economic results of an international naturalistic studyS Kasper, M Jones, I Duchesne, et al.
Pageof 50

Showing results (91-100 of 497) with videos related to

Sort By:
Pageof 50
International Clinical Psychopharmacology|July 21, 1998
Side effects, dropouts from treatment and cost consequencesS A Montgomery, S Kasper
Lancet (London, England)|December 3, 1994
Risperidone for Tourette's syndromeM Stamenkovic, H Aschauer, S Kasper
Science (New York, N.Y.)|August 5, 1977
Hexagonal (wurtzite) siliconJ S Kasper, R H Wentorf
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|October 6, 2001
Quetiapine: efficacy and tolerability in schizophreniaS Kasper, J Tauscher, A Heiden
Medical Hypotheses|February 14, 2004
Biophotons, microtubules and CNS, is our brain a "holographic computer"?F Grass, H Klima, S Kasper
Wiener Klinische Wochenschrift|March 28, 1997
[Maintenance therapy with 20 mg fluoxetine. Results of an administration study of 1,737 depressed patients]S Kasper, B Hesselmann, W Wein
International Journal of Psychiatry in Clinical Practice|June 14, 2014
Recurrent brief depression: A frequent syndrome in clinical practiceJ Angst, S Kasper, E Weiller
International Journal of Psychiatry in Clinical Practice|June 17, 2014
Physical signs in psychiatry: a step towards evidence-based medicineRk Gupta, R Kumar, S Kasper
Zentralblatt Fur Chirurgie|January 1, 1996
[History of autologous blood transfusion in the 19th century]S M Kasper, A S Kasper
International Clinical Psychopharmacology|July 19, 2001
Risperidone olanzapine drug outcomes studies in schizophrenia (RODOS): health economic results of an international naturalistic studyS Kasper, M Jones, I Duchesne, et al.
Pageof 50